Study ID (Protocol Number)
CA180-385
 
STUDY LOCATIONS*


 




*Not all study site locations may be listed - please check back soon for updated
information. For more information regarding other participating countries, please
visit clinicaltrials.gov.
  STUDY NAME
Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
STUDY OVERVIEW
The purpose of this study is to identify if patients with malignancy harboring a Discoidin Domain Receptor 2 (DDR2) mutation or an inactivating B-RAF mutation will respond to Dasatinib.
 

 
The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.
Find A Study